Non–muscle-invasive bladder cancer (NMIBC) represents approximately 75% of newly diagnosed bladder cancer cases and carries a high risk of recurrence and progression despite standard intravesical Bacillus Calmette-Guérin (BCG) therapy (1). Patients with high-risk disease—including those with carcinoma in situ (CIS) or T1 lesions face significant un
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1007 Reached2 Comments
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Treatment of Recurrent Adult Medulloblastoma
2601 Reached1 Comments4 Likes
Black Lesion in Old Female
1972 Reached5 Comments11 Likes
NSCLC Treatment To Control Long-term Tumor Growth
216 Reached1 Comments